In this regard, SLC1A3 (EAAT1) has been identified to contribute to asparaginase resistance in prostate and breast cancer in which combined treatment with asparaginase and EAAT1 chemical inhibition restrains cancer cell proliferation and tumor progression (196). Here, SLC1A3 is linked to neoplasm.